Fulcrum Therapeutics (NASDAQ: FULC)
Fulcrum Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Fulcrum Therapeutics Company Info
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
News & Analysis
2 Soaring Biotech Stocks With More Fuel in the Tank
These recent winners still have a long way to run.
Why Fulcrum Therapeutics Popped Again on Tuesday
Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.